

2018 Current Fiscal Year Report: National Cancer Institute Board of Scientific Advisors

Report Run Date: 06/05/2019 11:06:03 AM

1. Department or Agency

Department of Health and Human Services

2. Fiscal Year

2018

3. Committee or Subcommittee

National Cancer Institute Board of Scientific Advisors

3b. GSA Committee No.

1483

4. Is this New During Fiscal Year? 5. Current Charter 6. Expected Renewal Date 7. Expected Term Date

No 10/08/2017 10/08/2019

8a. Was Terminated During Fiscal Year? 8b. Specific Termination Authority 8c. Actual Term Date

No

9. Agency Recommendation for Next Fiscal Year 10a. Legislation Req to Terminate? 10b. Legislation Pending?

Continue Not Applicable Not Applicable

11. Establishment Authority Authorized by Law

12. Specific Establishment Authority 13. Effective Date 14. Committee Type 14c. Presidential?

42 U.S.C. 285a-2(b)(7) 11/20/1985 Continuing No

15. Description of Committee Scientific Technical Program Advisory Board

16a. Total Number of Reports 16b. No Reports for this Fiscal Year

17a. Open Meetings 3 17b. Closed Meetings 0 17c. Partially Closed Meetings 0 17d. Total Meetings and Dates 3

Purpose	Start	End
Program Advisory and/or Policy	11/29/2017	- 11/29/2017
Program Advisory and/or Policy	03/20/2018	- 03/20/2018
Program Advisory and/or Policy	06/26/2018	- 06/27/2018

Number of Committee Meetings Listed: 3

	Current FY	Next FY
18a(1). Personnel Pmts to Non-Federal Members	\$19,800.00	\$19,800.00
18a(2). Personnel Pmts to Federal Members	\$0.00	\$0.00
18a(3). Personnel Pmts to Federal Staff	\$81,302.00	\$85,925.00
18a(4). Personnel Pmts to Non-Member Consultants	\$1,400.00	\$1,400.00
18b(1). Travel and Per Diem to Non-Federal Members	\$46,555.00	\$47,127.00
18b(2). Travel and Per Diem to Federal Members	\$0.00	\$0.00
18b(3). Travel and Per Diem to Federal Staff	\$0.00	\$0.00
18b(4). Travel and Per Diem to Non-member Consultants	\$2,844.00	\$2,883.00
18c. Other(rents,user charges, graphics, printing, mail, etc.)	\$50,587.00	\$51,599.00

18d. Total	\$202,488.00	\$208,734.00
19. Federal Staff Support Years (FTE)	0.40	0.50

20a. How does the Committee accomplish its purpose?

The Board is composed of members who are distinguished scientists from outside the NCI and representatives from the advocacy community. The Board provides scientific advice on a wide variety of matters concerning scientific program policy, progress and future direction of the extramural research programs, and concept review of extramural program initiatives. This includes the evaluation of NCI awarded grants, oversight of concept review of cooperative agreements and contracts initiatives and those activities which it considers meritorious and consistent with the Institute's programs. The advisory role of the Board is scientific and does not include deliberation on matters of public policy. In 2018, the BSA was presented reports on various topics related to cancer research in general as well as legislative matters. BSA members provided insights regarding a report from the BSA Ad Hoc Subcommittee on Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) Malignancy. As a result, they approved the formation of a BSA Ad Hoc Working Group on Immunology of Therapies and Vaccines and Research Structure to provide further discussion and prioritization of the immunological aspects of developing therapeutic and preventative therapies and vaccines for virus-induced malignancies; understanding the interactions between the immune system and oncogenesis in tumor development; and understanding transmission of oncogenic viruses that cause HIV malignancies, especially KSHV and ways that the research infrastructure for AIDS-associated malignancies could be enhanced. The Board reviewed and deliberated on request for application (RFA) concepts covering a wide variety of topics including the following: Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (New RFA); Small Business Innovation Research (SBIR) Phase IIB Bridge Awards to Accelerate the Development of Cancer-Focused Technologies Toward Commercialization (Re-issue RFA); NCI Community Oncology Research Program (NCORP) (Re-issue RFA); AIDS and Cancer Specimen Resource (ACSR) (Re-issue RFA/Cooperative Agreement [Coop. Agr.] – Limited Competition); Improving the Reach and Quality of Cancer Care in Rural Populations (New RFA); Tobacco Cessation Interventions Among People Living with HIV/AIDS (New RFA/Coop. Agr.); Cancer Preventive Agent Development Program: Early Phase Clinical Research (New RFA/Coop. Agr.); Cooperative Human Tissue Network (CHTN) (Re-issue RFA/Coop. Agr.); Pathway to Independence Awards for Outstanding Early-Stage Postdoctoral Fellows (K88/R00) (New RFA); NCI Awardee Skills Development Consortium (NASDC) (New RFA/Coop. Agr.); U.S.-China Program for Biomedical Collaborative Research (Re-issue RFA); Early Clinical Trials of New Anticancer Agents with Phase 1 and 2 Emphasis (Re-Issue RFA/Coop. Agr.);

Immuno-Oncology Translation Network (IOTN) (New RFA/Coop. Agr.); Implementation Science Center for Cancer Control (IS-C3) (New RFA); Communications and Decision Making in the Context of Risk and Uncertainty for Individuals with Inherited Cancer Syndromes (New RFA); Research to Develop Evidence-Based Approaches to Patient Engagement (New RFA/Coop. Agr.); and Patient Engagement for Priority Cancer Sequencing (PE4PC-Seq) (New RFA/Coop. Agr.).

20b. How does the Committee balance its membership?

The Board consists of up to 35 members, including the Chair, appointed by the Director, NCI, from authorities knowledgeable in the fields of laboratory, clinical and biometric research, clinical cancer treatment, cancer etiology, and cancer prevention and control, with emphasis on training and experience in the various disciplines and fields related to scientific areas relevant to carcinogenesis, cancer biology and diagnosis, cancer center administration, medicine, radiological and surgical oncology, cancer chemotherapy, cancer epidemiology, cancer prevention and control, cancer education, cancer information services, community outreach, biological, chemical and physical carcinogenesis, DNA repair and effects, tumor biology and immunology, humoral and cellular immunity, hematopoiesis, cell differentiation and transformation, oncogenes and growth factors, molecular and structural biology and genetic regulation, viral oncology, vaccine development, transplantation, chemotherapy, clinical trial design, management and evaluation, pharmacology, drug development and developmental therapeutics, genetic and immunotherapies, pathology, diagnostic research and cytogenetics, biological response modifiers, imaging, nutrition, survey research, epidemiology, biostatistics, rehabilitation, psychology and behavioral medicine, public health and community oncology, quality of life, pain management, cancer detection and diagnosis, cancer treatment and restorative care, dentistry, nursing, public health, nutrition, education of health professionals, medical oncology, surgery, radiotherapy, gynecologic oncology, pediatric oncology, pathology, and biostatistics. Geographical, gender, ethnic and racial considerations are addressed in selecting members for appointment to the Board.

20c. How frequent and relevant are the Committee Meetings?

Meetings are held not less than three times a year. The committee met three times during this reporting period. The Board met jointly with the National Cancer Advisory Board for the November 2017 and June 2018 meetings. The Board also met in March 2018. The Board's deliberations are an indispensable part of the review of a very large part of the Institute's extramural program, as well as concept review of grant and contract initiatives in the extramural research program. According to the Board's charter, approximately three formal meetings are held each year for the review of the extramural programs and concept review of Request for Applications (RFAs); cooperative agreements; and

research and development contracts. The BSA Ad hoc Working Group on Immunology of Therapies and Vaccines and Research Structure met on June 13, 2018.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

This Board is composed of recognized biomedical research authorities from outside the NIH in order to secure unbiased and objective evaluations of extramural research programs. Their recommendations are invaluable because the complex nature of the research requires a unique balance and breadth of expertise not available at NIH or from other established sources.

20e. Why is it necessary to close and/or partially closed committee meetings?

N/A

21. Remarks

Reports: This committee did not produce any public reports. Members: Joseph DeSimone left the committee on 4/30/18. The terms for Kenneth Anderson, Dafna Bar-Sagi, Ethan Basch, Arul Chinnaiyan, Chi Dang, Karen Emmons, Maria Martinez, Luis Parada, Mary Smith, and Cheryl Walker have changed due to administrative extensions. As such, their term of service end dates are different than what was reported on the FY17 ACR. Costs: The operating costs for FY 18 are lower due to the March BSA meeting being held virtually versus in person. The DFO and Committee Decision Maker positions are held by the same individual because of the assignment of responsibilities within the Institute.

Designated Federal Officer

PAULETTE S. GRAY DIRECTOR, DIVISION OF EXTRAMURAL ACTIVITIES, NCI

Committee Members	Start	End	Occupation	Member Designation
ANDERSON, KENNETH	12/18/2013	12/28/2018	KRAFT FAMILY PROFESSOR OF MEDICINE	Special Government Employee (SGE) Member Special
BAR-SAGI, DAFNA	10/29/2013	12/28/2018	VICE DEAN FOR SCIENCE, SENIOR VICE PRESIDENT, AND CHIEF SCIENTIFIC OFFICER	Government Employee (SGE) Member Special
BASCH, ETHAN	01/27/2013	09/30/2018	ASSOCIATE PROFESSOR	Government Employee (SGE) Member Special
BECICH, MICHAEL	11/27/2016	06/30/2021	PROFESSOR, PATHOLOGY INFORMATION SCIENCES/TELECOMMUNICATIONS, CLINICAL/TRANSLATIONAL	Government Employee (SGE) Member

BHATIA, SANGEETA	11/07/2011	12/31/2017	JOHN J. AND DOROTHY WILSON PROFESSOR	Special Government Employee (SGE) Member
BONDY, MELISSA	11/26/2017	06/30/2021	PROFESSOR AND ASSOCIATE DIRECTOR	Special Government Employee (SGE) Member
CHINNAIYAN, ARUL	08/17/2010	09/30/2018	DIRECTOR, MICHIGAN CENTER FOR TRANSLATIONAL PATHOLOGY	Special Government Employee (SGE) Member
COLDITZ, GRAHAM	01/27/2013	06/30/2019	NIESS-GAIN PROFESSOR OF SURGERY	Special Government Employee (SGE) Member
COUNTER, CHRISTOPHER	02/05/2017	06/30/2021	PROFESSOR OF PHARMACOLOGY AND CANCER BIOLOGY AND ASSISTANT PROFESSOR OF RADIATION ONCOLOGY	Special Government Employee (SGE) Member
DANG, CHI	07/01/2014	09/30/2018	PROFESSOR OF MEDICINE, DIVISION OF HEMATOLOGY-ONCOLOGY	Special Government Employee (SGE) Member
DESIMONE, JOSEPH	02/22/2015	04/30/2018	CHANCELLOR'S EMINENT PROFESSOR OF CHEMISTRY	Special Government Employee (SGE) Member
DIMAIO, DANIEL	02/25/2013	12/31/2017	WALDEMAR VON ZEDTWITZ PROFESSOR AND VICE CHAIRMAN OF GENETICS	Special Government Employee (SGE) Member
EMMONS, KAREN	11/20/2011	09/30/2018	VICE PRESIDENT	Special Government Employee (SGE) Member
FERRANS, CAROL	03/06/2016	06/30/2020	ASSOCIATE DEAN FOR RESEARCH	Special Government Employee (SGE) Member
HUGHES-HALBERT, CHANITA	01/27/2013	12/31/2017	PROFESSOR AND ENDOWED CHAIR	Special Government Employee (SGE) Member
LACEY, JAMES	03/06/2016	06/30/2020	ASSOCIATE PROFESSOR	Special Government Employee (SGE) Member
MARTINEZ, MARIA	10/07/2015	09/30/2018	PROFESSOR	Special Government Employee (SGE) Member
PARADA, LUIS	11/07/2011	09/30/2018	ALBERT C FOSTER CHAIR DIRECTOR, BRAIN TUMOR CENTER	Special Government Employee (SGE) Member

PLEVRITIS, SYLVIA	02/05/2017	06/30/2021	PROFESSOR	Special Government Employee (SGE) Member
QUALE, DIANE	09/05/2014	06/30/2019	CO-FOUNDER AND PRESIDENT	Special Government Employee (SGE) Member
ROUSSEL (SHERR), MARTINE	02/25/2013	06/30/2020	ST. JUDE CHILDREN'S RESEARCH'S ENDOWED CHAIR IN MOLECULAR ONCOGENESIS	Special Government Employee (SGE) Member
SCHREIBER, ROBERT	11/26/2017	06/30/2021	ANDREW M. AND JANE M. BURSKY DISTINGUISHED PROFESSOR	Special Government Employee (SGE) Member
SEEWALDT, VICTORIA	03/20/2016	06/30/2020	RUTH ZIGLER PROFESSOR	Special Government Employee (SGE) Member
SHANNON, KEVIN	01/27/2013	06/30/2020	ROMA AND MARVIN AUERBACK DISTINGUISHED PROFESSOR IN PEDIATRIC MOLECULAR ONCOLOGY	Special Government Employee (SGE) Member
SMITH, MARY LOU	02/25/2013	09/30/2018	CO-FOUNDER	Special Government Employee (SGE) Member
THOMPSON, IAN	11/26/2017	06/30/2021	PRESIDENT	Special Government Employee (SGE) Member
TUVESON, DAVID	11/26/2017	06/30/2021	ROY J. ZUCKERBERG PROFESSOR	Special Government Employee (SGE) Member
WALKER, CHERYL	05/05/2013	09/30/2018	DIRECTOR, CENTER FOR PRECISION ENVIRONMENTAL HEALTH, PROFESSOR, DEPARTMENT OF MOLECULAR AND CELLULAR BIOLOGY	Special Government Employee (SGE) Member
WHITE, EILEEN	10/08/2014	06/30/2019	DISTINGUISHED PROFESSOR	Special Government Employee (SGE) Member
WHITE, KEVIN	10/27/2014	06/30/2019	JAMES AND KAREN FRANK FAMILY PROFESSOR	Special Government Employee (SGE) Member
WILLMAN, CHERYL	10/01/2017	06/30/2021	DIRECTOR AND CEO	Special Government Employee (SGE) Member

Number of Committee Members Listed: 31

Narrative Description

The goal of NIH research is to acquire new knowledge to help prevent, detect, diagnose, and treat disease and disability, from the rarest genetic disorder to the common cold. The NIH mission is to uncover new knowledge that will lead to better health for everyone. NIH works toward that mission by the National Cancer Institute Board of Scientific Advisor's (BSA). The BSA is composed of distinguished scientists from outside the NCI and representatives from the advocacy community. The BSA provides scientific advice on a wide variety of matters concerning scientific program policy, reviews the progress and future direction of the extramural research programs, and concept review of extramural program initiatives. This includes the oversight of research and development, concept review of request for applications, cooperative agreements, initiatives and other programmatic activities. The advisory role of the BSA is scientific and does not include deliberation on matters of public policy. The BSA represents the scientific community's voice in the extramural science the NCI supports. As such, the Board advises the NCI leadership on the progress and future direction of the Institute's Extramural Research Program. The Board evaluates NCI extramural programs, and reviews ideas for new research opportunities and solicitations to ensure that a concept is meritorious and consistent with the Institute's mission. Additionally, the BSA believes it is important to interact with and receive feedback from the clinical, population science, and laboratory research communities affected by NCI policies. The BSA's deliberations are an indispensable part of the review of a very large part of the Institute's extramural program.

What are the most significant program outcomes associated with this committee?

Checked if Applies

- Improvements to health or safety
- Trust in government
- Major policy changes
- Advance in scientific research
- Effective grant making
- Improved service delivery
- Increased customer satisfaction
- Implementation of laws or regulatory requirements
- Other

Outcome Comments

Based on the approval of the various RFA and RFP concepts, significant advances in cancer research could lead to new treatments, prevention and control initiatives, and behavioral modifications and cures for different cancer sites. Another outcome is the

annual posting of the RFA Report.

What are the cost savings associated with this committee?

Checked if Applies

- None
- Unable to Determine
- Under \$100,000
- \$100,000 - \$500,000
- \$500,001 - \$1,000,000
- \$1,000,001 - \$5,000,000
- \$5,000,001 - \$10,000,000
- Over \$10,000,000
- Cost Savings Other

Cost Savings Comments

Meetings are held not less than three times a year. The committee met three times during this reporting period. The Board met jointly with the National Cancer Advisory Board for the November 2017 and June 2018 meetings. The Board also met in March 2018. Additionally, RFA and RFP concepts are reviewed annually to determine the need for reissuance based on the Board recommendations. Ad hoc Subcommittee and/or working group meetings are held to gather information. Recommendations are reported back at a full board meeting where advice is given to the Institute. The BSA supports the Institute in meeting its mission and as a result even though it can't be calculated, there are substantive savings.

What is the approximate Number of recommendations produced by this committee for the life of the committee?

279

Number of Recommendations Comments

1. A motion to concur on the Office of the Director's (OD's) request for applications (RFA) titled "Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV)" was approved unanimously. 2. A motion to concur on the OD's re-issue RFA titled "Small Business Innovation Research (SBIR) Phase II B Bridge Awards to Accelerate the Development of Cancer-Focused Technologies Toward Commercialization" was approved unanimously. 3. A motion to concur on the Division of Cancer Prevention's re-issue RFA titled "NCI Community Oncology Research Program" was approved unanimously. 4. A motion to concur on the OD's re-issue RFA/Cooperative Agreement (Coop. Agr.) (Limited Competition) titled "AIDS and Cancer Specimen

Resource (ACSR)” was approved unanimously. 5. A motion to establish a BSA Ad Hoc Working Group on Immunology of Therapies and Vaccines and Research Structure was approved unanimously. 6. A motion to concur on the Division of Cancer Control and Population Sciences’ (DCCPS’s) RFA entitled “Improving the Reach and Quality of Cancer Care in Rural Populations” was approved unanimously. 7. A motion to concur on DCCPS’s RFA/Cooperative Agreement (Coop. Agr.) entitled “Tobacco Cessation Interventions Among People Living with HIV/AIDS” was approved unanimously. 8. A motion to concur on the Division of Cancer Prevention’s RFA/Coop. Agr. entitled “Cancer Preventive Agent Development Program: Early Phase Clinical Research” was approved with 23 ayes, zero nays, and 1 abstention. 9. A motion to concur on the re-issuance of the Division of Cancer Treatment and Diagnosis’s RFA/Coop. Agr. entitled “Cooperative Human Tissue Network (CHTN)” was approved with 22 ayes, zero nays, and 2 deferrals, with the consideration to broaden the CHTN geographically to increase racial and ethnic representation in the samples that reflect the diversity of the U.S. population. 10. A motion to accept the report of the 21 June 2017 BSA Ad Hoc HIV and AIDS Malignancy Subcommittee meeting was approved unanimously. 11. A motion to accept the minutes of the March 20, 2018 BSA meeting was approved unanimously. 12. A motion to concur on the Office of the Director’s (OD’s) RFA entitled “Pathway to Independence Awards for Outstanding Early-Stage Postdoctoral Fellows (K88/00)” was approved with 12 ayes, 7 nays, and 0 abstentions, with the stipulation that applications not be discipline-specific. 13. A motion to concur on the OD’s RFA/Cooperative Agreement (Coop. Agr.) entitled “NCI Awardee Skills Development Consortium (NASDC)” was approved unanimously. 14. A motion to concur on the OD’s re-issue RFA entitled “U.S.-China Program for Biomedical Collaborative Research” was approved unanimously. 15. A motion to concur on the Division of Cancer Treatment and Diagnosis’ re-issue RFA/Coop. Agr. entitled “Early Clinical Trials of New Anticancer Agents with Phase 1 and 2 Emphasis” was approved unanimously. 16. A motion to concur on the Division of Cancer Biology’s RFA/Coop. Agr. entitled “Immuno-Oncology Translation Network (IOTN)” was approved unanimously. 17. A motion to concur on the Division of Cancer Control and Population Science’s (DCCPS’s) RFA entitled “Implementation Science Center for Cancer Control (IS-C3)” was approved unanimously. 18. A motion to concur on the DCCPS’s RFA entitled “Communications and Decision Making in the Context of Risk and Uncertainty for Individuals with Inherited Cancer Syndromes” was approved unanimously. 19. A motion to defer on the DCCPS’s RFA/Coop. Agr. entitled “Research to Develop Evidence-Based Approaches to Patient Engagement” was approved unanimously. 20. A motion to defer on the DCCPS’s RFA/Coop. Agr. entitled “Patient Engagement for Priority Cancer Sequencing (PE4PC-Seq)” was approved unanimously.

What is the approximate Percentage of these recommendations that have been or

will be Fully implemented by the agency?

90%

% of Recommendations Fully Implemented Comments

The percentage of recommendations implemented as stated above was developed at the time the Annual Comprehensive Review report was prepared. Additional information is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at <http://report.nih.gov>

What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?

10%

% of Recommendations Partially Implemented Comments

The percentage of recommendations implemented stated above was developed at the time the Annual Comprehensive Review report was prepared. Additional information is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at <http://report.nih.gov>.

Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?

Yes No Not Applicable

Agency Feedback Comments

The NCI Director's Report is presented at each Board meeting. Each NCI Division gives an update regarding progress of approved RFAs, cooperative agreements and contract concepts. Also, the Annual RFA Report is presented at each November/December Joint BSA/National Cancer Advisory Board meeting to show RFAs published and reviewed. A list of action items are assigned to individual NCI staff with specific time frames with deadlines.

What other actions has the agency taken as a result of the committee's advice or recommendation?

Checked if Applies

Reorganized Priorities	<input checked="" type="checkbox"/>
Reallocated resources	<input checked="" type="checkbox"/>
Issued new regulation	<input type="checkbox"/>
Proposed legislation	<input type="checkbox"/>
Approved grants or other payments	<input type="checkbox"/>
Other	<input type="checkbox"/>

Action Comments

Priorities are reorganized based on motions made by Board members regarding RFA and RFP concepts. Resources are allocated based on approved concepts.

Is the Committee engaged in the review of applications for grants?

No

Grant Review Comments

NA

How is access provided to the information for the Committee's documentation?

Checked if Applies

Contact DFO	<input checked="" type="checkbox"/>
Online Agency Web Site	<input checked="" type="checkbox"/>
Online Committee Web Site	<input checked="" type="checkbox"/>
Online GSA FACA Web Site	<input checked="" type="checkbox"/>
Publications	<input checked="" type="checkbox"/>
Other	<input checked="" type="checkbox"/>

Access Comments

Information on the BSA can be found at the NCI Division of Extramural Activities: Advisory Boards, Committees and Review Groups website at

<http://deainfo.nci.nih.gov/advisory/bsa/bsa.htm>. Each NCI committee's charter, minutes, agenda, roster, future meeting dates, meeting PowerPoint presentations and reports is located here. Additionally, the public may view the BSA meetings (both live and on demand) via the NIH Videocast at the following website: <http://videocast.nih.gov/>.